The estimated Net Worth of Russell Barrans is at least $1.48 Миллион dollars as of 11 June 2021. Mr. Barrans owns over 18,180 units of Evofem Biosciences Inc stock worth over $4,217 and over the last 7 years he sold EVFM stock worth over $107,478. In addition, he makes $1,372,820 as Chief Commercial Officer at Evofem Biosciences Inc.
Sign up
Mr. Barrans EVFM stock SEC Form 4 insiders trading
Russell has made over 6 trades of the Evofem Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 18,180 units of EVFM stock worth $20,725 on 11 June 2021.
The largest trade he's ever made was buying 18,180 units of Evofem Biosciences Inc stock on 11 June 2021 worth over $20,725. On average, Russell trades about 1,643 units every 40 days since 2018. As of 11 June 2021 he still owns at least 468,552 units of Evofem Biosciences Inc stock.
You can see the complete history of Mr. Barrans stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Russell Barrans biography
Russell (Russ) Barrans serves as Chief Commercial Officer of the Company. Mr. Barrans has over 26 years in the women’s healthcare pharmaceuticals and biotechnology space. As the Chief Commercial Officer, he is responsible for the commercial launch and lifecycle management of the Evofem product portfolio, oversees manufacturing and supply chain, and provides executive leadership to the sales and marketing team. Prior to joining Evofem, Mr. Barrans was the Senior Director of Women’s Healthcare Marketing for Teva Pharmaceuticals from 2012 to June 2015. With significant tenure in life sciences and pharmaceutical companies, Mr. Barrans has held senior level positions at global and domestic companies including Bayer Healthcare and Wyeth Pfizer (formerly Wyeth), as well as, being Chief Executive Officer of FusionRx, a strategic consulting firm servicing biotech and pharmaceutical brands of which Mr. Barrans was the founding partner. Mr. Barrans has overseen directed the launch of over half a dozen brands worldwide including the launch of Mirena, and Plan B One-Step OTC.
What is the salary of Russell Barrans?
As the Chief Commercial Officer of Evofem Biosciences Inc, the total compensation of Russell Barrans at Evofem Biosciences Inc is $1,372,820. There are 4 executives at Evofem Biosciences Inc getting paid more, with Saundra Pelletier having the highest compensation of $2,803,980.
What's Russell Barrans's mailing address?
Russell's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130.
Insiders trading at Evofem Biosciences Inc
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link и Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.
What does Evofem Biosciences Inc do?
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
What does Evofem Biosciences Inc's logo look like?
Complete history of Mr. Barrans stock trades at Evofem Biosciences Inc
Evofem Biosciences Inc executives and stock owners
Evofem Biosciences Inc executives and other stock owners filed with the SEC include:
-
Saundra Pelletier,
President, Chief Executive Officer, Director -
Kelly Culwell,
Chief Medical Officer -
Saundra Pelletier,
Pres, CEO & Director -
Thomas Lynch,
Chairman of the Board -
Russell Barrans,
Chief Commercial Officer -
Justin File,
Chief Financial Officer -
Justin J. File,
Chief Financial Officer -
Russell Barrans,
Chief Commercial Officer -
Tony O'Brien,
Independent Director -
William Hall,
Independent Director -
Colin Rutherford,
Independent Director -
Gillian Greer,
Independent Director -
Kim Kamdar,
Independent Director -
Amy Raskopf,
IR Contact Officer -
Lisa Rarick,
Independent Director -
Alexander Fitzpatrick,
Executive Vice President, General Counsel, Secretary -
Dr. Kelly Culwell M.D.,
Chief Medical Officer -
Kathy Gallo-Doyle,
VP of Sales -
Alexander A. Fitzpatrick Esq.,
Exec. VP, Gen. Counsel & Sec. -
Biopharma, Inc. Pdl,
10% owner -
Research Corp Acacia,
10% owner -
Anthony Stephen O'brien,
Director -
Yan Zhang,
CFO -
Ltd. Invesco,
10% owner -
Fund Solutions Ltd Link,
10% owner